AZD-7762 - CAS 860352-01-8
Catalog number:
860352-01-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Checkpoint Kinase (Chk)
Description:
AZD-7762 is a synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Appearance:
white solid powder
Synonyms:
AZD 7762; AZD7762.
MSDS:
Inquire
Current Developer:
AstraZeneca.
1.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
Baranski Z1, Booij TH1, Cleton-Jansen AM2, Price LS1,3, van de Water B1, Bovée JV2, Hogendoorn PC2, Danen EH1. J Pathol. 2015 Jul;236(3):348-59. doi: 10.1002/path.4528. Epub 2015 Mar 30.
Conventional high-grade osteosarcoma is the most common primary bone sarcoma, with relatively high incidence in young people. In this study we found that expression of Aven correlates inversely with metastasis-free survival in osteosarcoma patients and is increased in metastases compared to primary tumours. Aven is an adaptor protein that has been implicated in anti-apoptotic signalling and serves as an oncoprotein in acute lymphoblastic leukaemia. In osteosarcoma cells, silencing Aven triggered G2 cell-cycle arrest; Chk1 protein levels were attenuated and ATR-Chk1 DNA damage response signalling in response to chemotherapy was abolished in Aven-depleted osteosarcoma cells, while ATM, Chk2 and p53 activation remained intact. Osteosarcoma is notoriously difficult to treat with standard chemotherapy, and we examined whether pharmacological inhibition of the Aven-controlled ATR-Chk1 response could sensitize osteosarcoma cells to genotoxic compounds.
2.Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F1, Bhupathi D2, Sun JD3, Liu Q4, Ahluwalia D5, Wang Y6, Matteucci MD7, Hart CP8. BMC Cancer. 2015 May 21;15:422. doi: 10.1186/s12885-015-1387-6.
BACKGROUND: The hypoxia-activated prodrug TH-302 is reduced at its nitroimidazole group and selectively under hypoxic conditions releases the DNA cross-linker bromo-isophosphoramide mustard (Br-IPM). Here, we have explored the effect of Chk1 inhibition on TH-302-mediated pharmacological activities.
3.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C, Rawlinson R, Massey AJ1. BMC Cancer. 2014 Aug 7;14:570. doi: 10.1186/1471-2407-14-570.
BACKGROUND: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects.
4.Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Liu Y1, Kwiatkowski DJ2. Mol Cancer Ther. 2015 Jan;14(1):174-82. doi: 10.1158/1535-7163.MCT-14-0622-T. Epub 2014 Oct 27.
Invasive bladder cancer has high morbidity and nearly uniform mortality when metastatic, with no therapeutic improvement in many years. Although chemotherapy combined with Chk1 inhibition has been investigated in several cancer types in which TP53 mutation is seen, this combination treatment approach has not been studied in bladder cancer. Recently, cancer genome sequencing efforts have identified CDKN1A (p21) mutations at 14% frequency in invasive bladder cancer, co-occurring half the time with TP53 mutations. We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor. Here, we show that TP53-CDKN1A double-mutant bladder cancer cell lines, 647V and RT-112, have a remarkable increase in p-Chk1 levels and G2-M arrest in response to gemcitabine treatment, with a heightened sensitivity to combination treatment with gemcitabine and either Chk1 inhibitor PF477736 or AZD7762, in comparison with other bladder cancer cell lines (either TP53 or p21 deficient).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Checkpoint Kinase (Chk) Products


CAS 405168-58-3 CHIR-124

CHIR-124
(CAS: 405168-58-3)

CHIR-124 is a quinolone-based small molecule Chk1 inhibitor, that is structurally unrelated to other known inhibitors of Chk1. It potently and selectively inhib...

CAS 516480-79-8 BML-277

BML-277
(CAS: 516480-79-8)

BML-277 is a selective APT-competitive inhibitor of the DNA damage response signaling enzyme CHK2 ( IC50 =15 nM).

CAS 952021-60-2 PF-477736

PF-477736
(CAS: 952021-60-2)

PF-477736 is a proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits...

SCH900776 S-isomer
(CAS: 891494-64-7)

SCH900776 S-isomer is the S-isomer form of SCH900776, which is a potent, selective and orally bioavailable inhibitor of checkpoint kinase Chk1. It can be used a...

CAS 1234015-55-4 Prexasertib mesylate

Prexasertib mesylate
(CAS: 1234015-55-4)

Prexasertib, also known as LY2606368, is an ATP-competitive CHK1 inhibitor (Ki= 0.9 nmol/L), with minor activity against CHK2 and RSK with IC50= 8 nM and 9 nM r...

CCT245737
(CAS: 1489389-23-2)

CCT245737, a nitrogen heterocycle compound, has been found to be a CHK1 inhibitor that could probable be effective in antineoplastic studies. It is still under ...

GDC-0425
(CAS: 1200129-48-1)

This active molecular is an selective Checkpoint kinase 1 (Chk1) inhibitors and it enhances gemcitabine efficacy in tumor xenograft models. GDC-0425 was safe an...

CCT241533 (hydrochloride)
(CAS: 1431697-96-9)

CCT241533 (hydrochloride) is the hydrochloride salt form of CCT241533. As a potent Chk2 inhibitor, CCT241533 blocked CHK2 activity in human tumor cell lines in ...

CAS 1234015-52-1 LY2606368

LY2606368
(CAS: 1234015-52-1)

LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.

CAS 1262849-73-9 CCT241533

CCT241533
(CAS: 1262849-73-9)

CCT241533, a Chk2 inhibitor, has been found to improve the effect of genotoxic cancer therapies. IC50: 3 nM.

CAS 891494-63-6 SCH900776

SCH900776
(CAS: 891494-63-6)

SCH900776, also known as MK-8776. is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activit...

CAS 911222-45-2 LY2603618

LY2603618
(CAS: 911222-45-2)

LY2603618 is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to ente...

CAS 860352-01-8 AZD-7762

AZD-7762
(CAS: 860352-01-8)

AZD-7762 is a synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, whic...

LY2606368 dihydrochloride
(CAS: 1234015-54-3)

The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic. I...

CAS 1278405-51-8 Thieno[2,3-d]pyridazine-7-carboxamide, 2-(3-fluorophenyl)-4-[(3S)-3-piperidinylamino]-, hydrochloride

Thieno[2,3-d]pyridazine-7-carboxamide, 2
(CAS: 1278405-51-8)

An inhibitor of CHK1 and CHK2

Chemical Structure

CAS 860352-01-8 AZD-7762

Quick Inquiry

Verification code

Featured Items